% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ferdinandus:302998,
      author       = {J. Ferdinandus and H. Kaul and A. Fosså and A.
                      Hüttmann$^*$ and F. Keil and Y.-D. Ko and F. Hitz and M.
                      Schwarz and C. Trenker and A. Kerkhoff and P. Staib and K.
                      Wille and I. Dresel and D. Hahn and B. Hertenstein and P.
                      Moosmann and U. Mey and S. Balabanov and T. Armytage and F.
                      Roncolato and J. C. Hellmuth and M. Hertzberg and C. Kobe
                      and W. Klapper and C. Baues and H.-T. Eich and S. Kreissl
                      and M. Fuchs and J. Jablonski and G. Schneider and H.
                      Tharmaseelan and D. A. Eichenauer and B. von Tresckow$^*$
                      and P. Borchmann and P. J. Bröckelmann},
      title        = {{P}ositron {E}mission {T}omography-{G}uided {B}rentuximab
                      {V}edotin, {E}toposide, {C}yclophosphamide, {D}oxorubicin,
                      {D}acarbazine, and {D}examethasone in {O}lder {P}atients
                      {W}ith {A}dvanced-{S}tage {C}lassic {H}odgkin {L}ymphoma:
                      {A} {P}rospective, {M}ulticenter, {S}ingle-{A}rm, {P}hase
                      {II} {C}ohort of the {G}erman {H}odgkin {S}tudy {G}roup
                      {HD}21 {T}rial.},
      journal      = {Journal of clinical oncology},
      volume       = {nn},
      issn         = {0732-183X},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2025-01445},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Positron emission tomography (PET)-guided therapy with 4-6
                      cycles of brentuximab vedotin, etoposide, cyclophosphamide,
                      doxorubicin, dacarbazine, and dexamethasone (BrECADD) is
                      highly effective in younger patients with advanced-stage
                      classic Hodgkin lymphoma (AS-cHL). We report feasibility and
                      efficacy of PET-guided BrECADD as first-line treatment in
                      older patients with AS-cHL.Patients with AS-cHL aged 61-75
                      years were enrolled in a phase II single-arm cohort of the
                      HD21 trial (ClinicalTrials.gov identifier: NCT02661503).
                      Patients with negative PET/computed tomography after
                      2×BrECADD (PET2) received a total of 4×BrECADD, while
                      PET2-positive patients received 6×BrECADD. The primary end
                      point was the centrally reviewed complete remission (CR)
                      rate after the end of chemotherapy (EOC). Secondary end
                      points included feasibility, adverse events,
                      treatment-related morbidity (TRMB), progression-free
                      survival (PFS), overall survival (OS), and health-related
                      quality of life (HRQoL).Between June 2020 and April 2023, 85
                      patients were enrolled, of whom 83 with a median age of 67
                      years (range, 61-75) were analyzed in the intention-to-treat
                      cohort. Most prevalent ≥grade 3 toxicities included
                      leukopenia (n = 80 $[96\%]),$ thrombocytopenia (n = 71
                      $[86\%]),$ anemia (n = 57 $[69\%]),$ and febrile neutropenia
                      (n = 46 $[55\%]).$ Forty-eight $(60\%)$ of 80 patients with
                      centrally reviewed PET2 were scheduled for 4×BrECADD and 32
                      $(40\%)$ for 6×BrECADD. Of these, 71 patients $(89\%)$
                      received the target number of cycles. Sixty-eight patients
                      $(82\%;$ $95\%$ CI, 72 to 90) achieved CR at EOC. PFS and OS
                      estimates at 2 years were $91.5\%$ $(95\%$ CI, 85 to 98) and
                      $90.8\%$ $(95\%$ CI, 84 to 98), respectively. No death was
                      attributed to study treatment. Initially, impaired HRQoL
                      scores improved during follow up and on average reached
                      population reference values.PET-guided BrECADD in older
                      patients is feasible and effective. With a PFS rate on par
                      with that of younger patients, short duration, and limited
                      anthracycline exposure, BrECADD is a valuable treatment
                      option also for older patients with AS-cHL.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40674676},
      doi          = {10.1200/JCO-25-00439},
      url          = {https://inrepo02.dkfz.de/record/302998},
}